Nuvalent Submits NDA for Neladalkib in ALK Lung Cancer
CAMBRIDGE, Mass., April 7, 2026 Nuvalent, Inc. has announced the submission of a New Drug Application (NDA) to the...
Nuvalent
Advertisement
FDA Accepts NDA for Nuvalent’s Zidesamtinib in ROS1+ NSCLC
Cambridge, Massachusetts — November 19, 2025 — Nuvalent, Inc. announced that the U.S. Food and Drug Administration (FDA) has...
Advertisement
